한글목차

또한, 알부민 시장의 성장은 제품 출시, 인수, 계약 등 주요 업계 기업들 사이에서 중요한 전략의 이행이 증가함에 따라 추진되고 있습니다.

예를 들어, 2020년 9월 생명 과학 연구 및 바이오 의약품 산업의 국제 주요 파트너인 Sartorius Group은 재조합 알부민 기반 솔루션 분야의 리더인 Albumedix Ltd의 인수를 발표했습니다. 또한 혈장 유래 의약품의 세계적인 선두 업체인 그리포르스는 알부민 포트폴리오의 최신 혁신인 ALBUTEIN FlexBag의 5% 및 25% 농도 출시를 발표했습니다. 이러한 전략적 움직임은 혁신을 추진할 뿐만 아니라 의료 및 바이오 의약품 산업의 진화하는 요구를 충족시켜 시장 성장을 가속합니다.

또한 기술적 진보는 알부민 시장 성장의 주요 촉진요인이 되었습니다. 제약 및 바이오테크놀러지 분야에서는 생산 공정과 정제 기술에 있어서 끊임없는 기술 혁신이 알부민 제품의 효율과 품질을 높이고 있습니다. 첨단 기술은 또한 새로운 알부민 기반 제제의 개발에 기여하고 약물 전달 시스템 및 진단에 응용을 확대하고 있습니다. 제조, 정제 및 분석의 정확도가 높아 불순물을 최소화한 고품질 알부민을 보장하며 엄격한 규제 기준을 충족합니다. 게다가, 기술의 발전은 알부민 제조를 위한 대체 공급원의 탐구를 용이하게 하고 공급망의 과제를 해결합니다. 기술과 알부민 생산의 시너지 효과는 기존 제품을 개선할 뿐만 아니라 최첨단 솔루션의 창출을 촉진하고 알부민 시장의 전반적인 확대에 박차를 가하고 있습니다.

알부민 시장은 유형, 용도, 판매 채널, 지역에 따라 구분됩니다. 유형별로는 인간 혈청 알부민, 소 혈청 알부민, 유전자 재조합 알부민으로 분류됩니다. 용도별로는 치료제, 제제 및 백신, 배지 성분 등으로 분류됩니다. 판매 채널별로는 기업간 거래(B2B) 및 소비자간 거래(B2C)로 분류됩니다. 지역별로는 북미(미국, 캐나다, 멕시코), 유럽(독일, 프랑스, 영국, 이탈리아, 스페인, 기타 유럽), 아시아태평양(일본, 중국, 인도, 호주, 한국, 기타 아시아태평양), 아시아태평양(브라질, 중국, 아라비아 및 기타 아시아태평양)에서 분석됩니다.

이해관계자를 위한 주요 이점

• 본 보고서에서는 2022년부터 2032년까지의 알부민 시장 분석의 시장 부문, 현재의 동향, 추정 및 동향 분석, 역학을 정량적으로 분석하여 알부민 시장의 유력한 기회를 확인합니다.
• 시장 성장 촉진요인, 시장 성장 억제요인, 시장 기회와 관련된 정보와 함께 시장 조사를 제공합니다.
• Porter's Five Forces 분석은 이해관계자가 이익에 중점을 둔 비즈니스 결정을 내리고 공급업체 및 구매자의 네트워크를 강화할 수 있도록 구매자와 공급업체의 잠재력을 강조합니다.
• 알부민 시장의 세분화에 대한 자세한 분석은 시장 기회를 결정하는 데 도움이 됩니다.
• 각 지역의 주요 국가는 세계 시장에 대한 수익 공헌도에 따라 매핑됩니다.
• 시장 기업 포지셔닝은 벤치마킹을 용이하게 하고 시장 기업의 현재 포지션에 대한 명확한 이해를 제공합니다.
• 이 보고서는 지역별 및 세계의 알부민 시장 동향, 주요 기업, 시장 부문, 응용 분야 및 시장 성장 전략 분석을 포함합니다.

이 보고서에서 가능한 보고서 맞춤설정(추가 비용 및 일정이 있습니다.)

• 국가, 지역, 세계 수준의 환자 및 역학 데이터
• 규제 가이드라인
• 고객의 관심에 특화된 추가 기업 프로파일
• 기업 프로파일의 확장 목록
• 과거 시장 데이터
• 상환 시나리오
• SWOT 분석

목차

제1장 서론

제2장 주요 요약

제3장 시장 개요

• 시장 정의 및 범위
• 주요 조사 결과
  • 영향요인
  • 주요 투자 기회
• Porter's Five Forces 분석
• 시장 역학
  • 성장 촉진요인
    • 수술 건수 증가
    • 헌혈에 대한 의식 증가
    • 의약품 개발에 있어서의 혈장 유래 알부민 사용 증가
  • 억제요인
    • 엄격한 정부 규제
  • 기회
    • 신흥 시장에서의 성장 기회

제4장 알부민 시장 : 유형별

• 개요
• 인간 혈청 알부민
• 소 혈청 알부민
• 유전자 변형 알부민

제5장 알부민 시장 : 용도별

• 개요
• 치료제
• 의약품 제제 및 백신
• 배지 성분
• 기타

제6장 알부민 시장 : 판매 채널별

• 개요
• B2C
• B2B
  • B2B 알부민 시장 : 유형별
    • 의약품 용도 알부민 시장 : 유형별
    • 비의약품 용도 알부민 시장 : 유형별

제7장 알부민 시장 : 지역별

• 개요
• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 독일
  • 프랑스
  • 영국
  • 이탈리아
  • 스페인
  • 기타
• 아시아태평양
  • 일본
  • 중국
  • 인도
  • 호주
  • 한국
  • 기타
• 라틴아메리카, 중동 및 아프리카
  • 브라질
  • 사우디아라비아
  • 남아프리카
  • 기타

제8장 경쟁 구도

• 서문
• 주요 성공 전략
• 주요 10개사의 제품 매핑
• 경쟁 대시보드
• 경쟁 히트맵
• 주요 기업의 포지셔닝(2022년)

제9장 기업 프로파일

• Merck KGaA
• Sartorius AG
• Octapharma AG
• Thermo Fisher Scientific Inc.
• Ventria Bioscience Inc.
• Grifols, SA
• CSL
• China Biologic Products Holdings, Inc
• Lazuline Bio
• Takeda Pharmaceutical Company Limited

영문목차

Furthermore, the growth of the albumin market is propelled by the increasing implementation of key strategies among major industry players, including product launches, acquisitions, and agreements. For instance, in September 2020, Sartorius Group, a leading international partner of life science research and the biopharmaceutical industry, announced acquisition of Albumedix Ltd, a leader in the field of recombinant albumin-based solutions. In addition, Grifols, a leading global producer of plasma-derived medicines, announced the launch of its latest albumin portfolio innovation, ALBUTEIN FlexBag (Albumin [Human] U.S.P.) in 5% and 25% concentrations. These strategic moves not only drive innovation but also foster market growth by catering to the evolving needs of the healthcare and biopharmaceutical industries.

In addition, technological advancements are key drivers of the growing albumin market. In the pharmaceutical and biotechnology sectors, continuous innovations in production processes and purification techniques enhance the efficiency and quality of albumin products. Advanced technologies also contribute to the development of novel albumin-based formulations, expanding their applications in drug delivery systems and diagnostics. Precision in manufacturing, purification, and analysis ensures high-quality albumin with minimal impurities, meeting stringent regulatory standards. In addition, technological progress facilitates the exploration of alternative sources for albumin production, addressing supply chain challenges. The synergy between technology and albumin production not only improves existing products but also fosters the creation of cutting-edge solutions, fueling the overall expansion of the albumin market.

The albumin market is segmented on the basis of type, application, sales channel, and region. On the basis of type, the market is categorized into human serum albumin, bovine serum albumin, and recombinant albumin. On the basis of application, it is classified into therapeutics, drug formulation & vaccines, component of media, and others. On the basis of sales channel, it is classified into business to business (B2B) and business to consumer (B2C). On the basis of region, the market is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, India, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

The major key players that operate in the global albumin market are Takeda Pharmaceutical Company Limited, Merck KGaA, Sartorius AG, Octapharma AG, Thermo Fisher Scientific Inc., Ventria Bioscience Inc, Grifols, S.A., CSL, China Biologic Products Holdings, Inc, and Lazuline Bio. The players have adopted investment, strategic alliance, product approval, clinical trials, expansion, agreement, and acquisition as the key strategies to expand their product portfolio.

Key Benefits For Stakeholders

• This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the albumin market analysis from 2022 to 2032 to identify the prevailing albumin market opportunities.
• The market research is offered along with information related to key drivers, restraints, and opportunities.
• Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
• In-depth analysis of the albumin market segmentation assists to determine the prevailing market opportunities.
• Major countries in each region are mapped according to their revenue contribution to the global market.
• Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
• The report includes the analysis of the regional as well as global albumin market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

• Quarterly Update and* (only available with a corporate license, on listed price)
• 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
• Free Upcoming Version on the Purchase of Five and Enterprise User License.
• 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
• 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
• Free data Pack on the Five and Enterprise User License. (Excel version of the report)
• Free Updated report if the report is 6-12 months old or older.
• 24-hour priority response*
• Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

• Patient/epidemiology data at country, region, global level
• Regulatory Guidelines
• Additional company profiles with specific to client's interest
• Expanded list for Company Profiles
• Historic market data
• Reimbursement Scenario
• SWOT Analysis

Key Market Segments

By Type

• Human Serum Albumin
• Bovine Serum Albumin
• Recombinant Albumin

By Application

• Therapeutics
• Drug Formulation and Vaccines
• Component of Media
• Other

By Sales Channel

• B2C
• B2B
  • Type
  • Pharmaceutical Applications

Type

• Non Pharmaceutical Applications

Type

By Region

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
• Asia-Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Rest of Asia-Pacific
• LAMEA
  • Brazil
  • Saudi Arabia
  • South Africa
  • Rest of LAMEA

Key Market Players:

• Octapharma AG
• Grifols, S.A.
• CSL
• Ventria Bioscience Inc.
• Lazuline Bio
• Takeda Pharmaceutical Company Limited
• Sartorius AG
• Merck KGaA
• Thermo Fisher Scientific Inc.
• China Biologic Products Holdings, Inc

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

• 1.1. Report description
• 1.2. Key market segments
• 1.3. Key benefits to the stakeholders
• 1.4. Research methodology
  • 1.4.1. Primary research
  • 1.4.2. Secondary research
  • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

• 2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

• 3.1. Market definition and scope
• 3.2. Key findings
  • 3.2.1. Top impacting factors
  • 3.2.2. Top investment pockets
• 3.3. Porter's five forces analysis
  • 3.3.1. Moderate bargaining power of suppliers
  • 3.3.2. Moderate threat of new entrants
  • 3.3.3. Moderate threat of substitutes
  • 3.3.4. Moderate intensity of rivalry
  • 3.3.5. Moderate bargaining power of buyers
• 3.4. Market dynamics
  • 3.4.1. Drivers
    • 3.4.1.1. Rise in number of surgical procedures
    • 3.4.1.2. Growing awareness regarding blood donations.
    • 3.4.1.3. Rise in use of plasma derived albumin in drug development
  • 3.4.2. Restraints
    • 3.4.2.1. Stringent government regulations
  • 3.4.3. Opportunities
    • 3.4.3.1. Growth opportunities in emerging markets

CHAPTER 4: ALBUMIN MARKET, BY TYPE

• 4.1. Overview
  • 4.1.1. Market size and forecast
• 4.2. Human Serum Albumin
  • 4.2.1. Key market trends, growth factors and opportunities
  • 4.2.2. Market size and forecast, by region
  • 4.2.3. Market share analysis by country
• 4.3. Bovine Serum Albumin
  • 4.3.1. Key market trends, growth factors and opportunities
  • 4.3.2. Market size and forecast, by region
  • 4.3.3. Market share analysis by country
• 4.4. Recombinant Albumin
  • 4.4.1. Key market trends, growth factors and opportunities
  • 4.4.2. Market size and forecast, by region
  • 4.4.3. Market share analysis by country

CHAPTER 5: ALBUMIN MARKET, BY APPLICATION

• 5.1. Overview
  • 5.1.1. Market size and forecast
• 5.2. Therapeutics
  • 5.2.1. Key market trends, growth factors and opportunities
  • 5.2.2. Market size and forecast, by region
  • 5.2.3. Market share analysis by country
• 5.3. Drug Formulation and Vaccines
  • 5.3.1. Key market trends, growth factors and opportunities
  • 5.3.2. Market size and forecast, by region
  • 5.3.3. Market share analysis by country
• 5.4. Component of Media
  • 5.4.1. Key market trends, growth factors and opportunities
  • 5.4.2. Market size and forecast, by region
  • 5.4.3. Market share analysis by country
• 5.5. Other
  • 5.5.1. Key market trends, growth factors and opportunities
  • 5.5.2. Market size and forecast, by region
  • 5.5.3. Market share analysis by country

CHAPTER 6: ALBUMIN MARKET, BY SALES CHANNEL

• 6.1. Overview
  • 6.1.1. Market size and forecast
• 6.2. B2C
  • 6.2.1. Key market trends, growth factors and opportunities
  • 6.2.2. Market size and forecast, by region
  • 6.2.3. Market share analysis by country
• 6.3. B2B
  • 6.3.1. Key market trends, growth factors and opportunities
  • 6.3.2. Market size and forecast, by region
  • 6.3.3. Market share analysis by country
  • 6.3.4. B2B Albumin Market by Type
    • 6.3.4.1. Pharmaceutical Applications Albumin Market by Type
    • 6.3.4.2. Non Pharmaceutical Applications Albumin Market by Type

CHAPTER 7: ALBUMIN MARKET, BY REGION

• 7.1. Overview
  • 7.1.1. Market size and forecast By Region
• 7.2. North America
  • 7.2.1. Key market trends, growth factors and opportunities
  • 7.2.2. Market size and forecast, by Type
  • 7.2.3. Market size and forecast, by Application
  • 7.2.4. Market size and forecast, by Sales Channel
  • 7.2.5. Market size and forecast, by country
    • 7.2.5.1. U.S.
    • 7.2.5.1.1. Market size and forecast, by Type
    • 7.2.5.1.2. Market size and forecast, by Application
    • 7.2.5.1.3. Market size and forecast, by Sales Channel
    • 7.2.5.2. Canada
    • 7.2.5.2.1. Market size and forecast, by Type
    • 7.2.5.2.2. Market size and forecast, by Application
    • 7.2.5.2.3. Market size and forecast, by Sales Channel
    • 7.2.5.3. Mexico
    • 7.2.5.3.1. Market size and forecast, by Type
    • 7.2.5.3.2. Market size and forecast, by Application
    • 7.2.5.3.3. Market size and forecast, by Sales Channel
• 7.3. Europe
  • 7.3.1. Key market trends, growth factors and opportunities
  • 7.3.2. Market size and forecast, by Type
  • 7.3.3. Market size and forecast, by Application
  • 7.3.4. Market size and forecast, by Sales Channel
  • 7.3.5. Market size and forecast, by country
    • 7.3.5.1. Germany
    • 7.3.5.1.1. Market size and forecast, by Type
    • 7.3.5.1.2. Market size and forecast, by Application
    • 7.3.5.1.3. Market size and forecast, by Sales Channel
    • 7.3.5.2. France
    • 7.3.5.2.1. Market size and forecast, by Type
    • 7.3.5.2.2. Market size and forecast, by Application
    • 7.3.5.2.3. Market size and forecast, by Sales Channel
    • 7.3.5.3. UK
    • 7.3.5.3.1. Market size and forecast, by Type
    • 7.3.5.3.2. Market size and forecast, by Application
    • 7.3.5.3.3. Market size and forecast, by Sales Channel
    • 7.3.5.4. Italy
    • 7.3.5.4.1. Market size and forecast, by Type
    • 7.3.5.4.2. Market size and forecast, by Application
    • 7.3.5.4.3. Market size and forecast, by Sales Channel
    • 7.3.5.5. Spain
    • 7.3.5.5.1. Market size and forecast, by Type
    • 7.3.5.5.2. Market size and forecast, by Application
    • 7.3.5.5.3. Market size and forecast, by Sales Channel
    • 7.3.5.6. Rest of Europe
    • 7.3.5.6.1. Market size and forecast, by Type
    • 7.3.5.6.2. Market size and forecast, by Application
    • 7.3.5.6.3. Market size and forecast, by Sales Channel
• 7.4. Asia-Pacific
  • 7.4.1. Key market trends, growth factors and opportunities
  • 7.4.2. Market size and forecast, by Type
  • 7.4.3. Market size and forecast, by Application
  • 7.4.4. Market size and forecast, by Sales Channel
  • 7.4.5. Market size and forecast, by country
    • 7.4.5.1. Japan
    • 7.4.5.1.1. Market size and forecast, by Type
    • 7.4.5.1.2. Market size and forecast, by Application
    • 7.4.5.1.3. Market size and forecast, by Sales Channel
    • 7.4.5.2. China
    • 7.4.5.2.1. Market size and forecast, by Type
    • 7.4.5.2.2. Market size and forecast, by Application
    • 7.4.5.2.3. Market size and forecast, by Sales Channel
    • 7.4.5.3. India
    • 7.4.5.3.1. Market size and forecast, by Type
    • 7.4.5.3.2. Market size and forecast, by Application
    • 7.4.5.3.3. Market size and forecast, by Sales Channel
    • 7.4.5.4. Australia
    • 7.4.5.4.1. Market size and forecast, by Type
    • 7.4.5.4.2. Market size and forecast, by Application
    • 7.4.5.4.3. Market size and forecast, by Sales Channel
    • 7.4.5.5. South Korea
    • 7.4.5.5.1. Market size and forecast, by Type
    • 7.4.5.5.2. Market size and forecast, by Application
    • 7.4.5.5.3. Market size and forecast, by Sales Channel
    • 7.4.5.6. Rest of Asia-Pacific
    • 7.4.5.6.1. Market size and forecast, by Type
    • 7.4.5.6.2. Market size and forecast, by Application
    • 7.4.5.6.3. Market size and forecast, by Sales Channel
• 7.5. LAMEA
  • 7.5.1. Key market trends, growth factors and opportunities
  • 7.5.2. Market size and forecast, by Type
  • 7.5.3. Market size and forecast, by Application
  • 7.5.4. Market size and forecast, by Sales Channel
  • 7.5.5. Market size and forecast, by country
    • 7.5.5.1. Brazil
    • 7.5.5.1.1. Market size and forecast, by Type
    • 7.5.5.1.2. Market size and forecast, by Application
    • 7.5.5.1.3. Market size and forecast, by Sales Channel
    • 7.5.5.2. Saudi Arabia
    • 7.5.5.2.1. Market size and forecast, by Type
    • 7.5.5.2.2. Market size and forecast, by Application
    • 7.5.5.2.3. Market size and forecast, by Sales Channel
    • 7.5.5.3. South Africa
    • 7.5.5.3.1. Market size and forecast, by Type
    • 7.5.5.3.2. Market size and forecast, by Application
    • 7.5.5.3.3. Market size and forecast, by Sales Channel
    • 7.5.5.4. Rest of LAMEA
    • 7.5.5.4.1. Market size and forecast, by Type
    • 7.5.5.4.2. Market size and forecast, by Application
    • 7.5.5.4.3. Market size and forecast, by Sales Channel

CHAPTER 8: COMPETITIVE LANDSCAPE

• 8.1. Introduction
• 8.2. Top winning strategies
• 8.3. Product mapping of top 10 player
• 8.4. Competitive dashboard
• 8.5. Competitive heatmap
• 8.6. Top player positioning, 2022

CHAPTER 9: COMPANY PROFILES

• 9.1. Merck KGaA
  • 9.1.1. Company overview
  • 9.1.2. Key executives
  • 9.1.3. Company snapshot
  • 9.1.4. Operating business segments
  • 9.1.5. Product portfolio
  • 9.1.6. Business performance
• 9.2. Sartorius AG
  • 9.2.1. Company overview
  • 9.2.2. Key executives
  • 9.2.3. Company snapshot
  • 9.2.4. Operating business segments
  • 9.2.5. Product portfolio
  • 9.2.6. Business performance
  • 9.2.7. Key strategic moves and developments
• 9.3. Octapharma AG
  • 9.3.1. Company overview
  • 9.3.2. Key executives
  • 9.3.3. Company snapshot
  • 9.3.4. Operating business segments
  • 9.3.5. Product portfolio
  • 9.3.6. Business performance
  • 9.3.7. Key strategic moves and developments
• 9.4. Thermo Fisher Scientific Inc.
  • 9.4.1. Company overview
  • 9.4.2. Key executives
  • 9.4.3. Company snapshot
  • 9.4.4. Operating business segments
  • 9.4.5. Product portfolio
  • 9.4.6. Business performance
• 9.5. Ventria Bioscience Inc.
  • 9.5.1. Company overview
  • 9.5.2. Key executives
  • 9.5.3. Company snapshot
  • 9.5.4. Operating business segments
  • 9.5.5. Product portfolio
• 9.6. Grifols, S.A.
  • 9.6.1. Company overview
  • 9.6.2. Key executives
  • 9.6.3. Company snapshot
  • 9.6.4. Operating business segments
  • 9.6.5. Product portfolio
  • 9.6.6. Business performance
  • 9.6.7. Key strategic moves and developments
• 9.7. CSL
  • 9.7.1. Company overview
  • 9.7.2. Key executives
  • 9.7.3. Company snapshot
  • 9.7.4. Operating business segments
  • 9.7.5. Product portfolio
  • 9.7.6. Business performance
• 9.8. China Biologic Products Holdings, Inc
  • 9.8.1. Company overview
  • 9.8.2. Key executives
  • 9.8.3. Company snapshot
  • 9.8.4. Operating business segments
  • 9.8.5. Product portfolio
• 9.9. Lazuline Bio
  • 9.9.1. Company overview
  • 9.9.2. Key executives
  • 9.9.3. Company snapshot
  • 9.9.4. Operating business segments
  • 9.9.5. Product portfolio
• 9.10. Takeda Pharmaceutical Company Limited
  • 9.10.1. Company overview
  • 9.10.2. Key executives
  • 9.10.3. Company snapshot
  • 9.10.4. Operating business segments
  • 9.10.5. Product portfolio
  • 9.10.6. Business performance
  • 9.10.7. Key strategic moves and developments